Francisco Leon,

CEO,

Tolerance Bio

Francisco Leon, MD, PhD, is the Founder and CEO of Tolerance Bio, focused on restoring, manipulating, and preserving the thymus to address immune diseases.

Francisco is a clinical and basic immunologist with a long career in academia (NIH), biopharma (BMS, MedImmune/AZ, Centocor/Janssen/JNJ), and as an entrepreneur, having served as CEO, CMO, and CSO of several companies.

He has led or participated in the development of 6 drugs which reached the market, most recently teplizumab (TZIELD®) for the delay or prevention of the onset of clinical type 1 diabetes, and has co-founded two biotech companies acquired by Pharma: Celimmune, acquired by Amgen in 2017, and Provention Bio, acquired by Sanofi in 2023.